RxDoctor Payments Data

Richard Vandevelde, OD

Optometrist · Brunswick, GANPI 1396757480

Payments from drug & device makers

$2,088in general payments, 2019–2025

Across 40 payments — averaging $52.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$870
  • Rxsight Inc$350
  • Johnson & Johnson Surgical Vision, Inc.$321
  • AbbVie$288
  • Bausch & Lomb Americas Inc.$125
  • Tarsus Pharmaceuticals, Inc.$115
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$2,088100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,088 in reported general payments places this provider in the 70th percentile of 1,285 optometrist providers in Georgia.

See all optometrist providers in Georgia

Medicare billing

Part B allowed, 2024
$51,484
Medicare patients
281
Services billed
582

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost126$47,082
RestasisCyclosporine47$36,678
RhopressaNetarsudil Mesylate29$12,046
CombiganBrimonidine Tartrate/Timolol28$10,620
Alphagan PBrimonidine Tartrate26$9,513
RocklatanNetarsudil Mesylat/Latanoprost13$4,428
Latanoprost486$3,716
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol33$3,330
Prednisolone Acetate64$2,740
Brinzolamide11$2,329
Timolol Maleate251$2,092
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat112$1,470
Brimonidine Tartrate162$1,368
Dorzolamide Hcl62$1,272
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha32$422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$288$103,893227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,285 optometrist providers in Georgia.

Other optometrist in Brunswick

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →